Overview

Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Amgen
Treatments:
Etanercept